CALGB 40101 - Cyclophosphamide and Doxorubicin (CA) 4 vs 6 cycles) Versus Paclitaxel (12 weeks vs 18 weeks) as Adjuant Therapy for Women with Node-Negative Breast Cancer: A 2x2 Factorial Phase III Randomized Study.
CALGB 40302 - 40302 Cancer And Leukemia Group B (CALGB): Endocrine Therapy With or Without Inhibition of EGF and Her2 Growth Factor Receptors: A Randomized, Double-Blind, Placebo-Controlled Phase Iii Trial of Fulvestrant with or Without Lapatinib (Gw572016) For Postmenopausal Women with Hormone Receptor Positive Advanced Breast Cancer
CALGB 49805 - 49805 Cancer and Leukemia Group B (CALGB), NCIC CTG: MA.17R. A Double Blind Randomization to Letrozole or Placebo for Women Previously Diagnosed With Primary Breast Cancer Completing Five Years of Adjuvant Aromatase Inhbitor Either as Initial Therapy or After Tamoxifen (Including Those in the MA.17 Study) Study Number: NCIC CTG: MA.17R
CALGB 70301 - Quality of Life, Employment and Informal Care Cost Analysis in Women Receiving Adjuvant Chemotherapy for Breast Cancer with 0-3 Positive Axillary Lymph Nodes. (Companion Study to CALGB 40101).
E5103 - E5103: A Double Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
GCC 0107 - Determination of the Level of Circulating PC-Cell Derived Growth Factor (PCDGF) in Breast Cancer Patients
GCC 0424 - A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer
GCC 0601 - A Prospective, Randomized, Double-Blind, Stratified, Multicenter, 2 Arm Trial of the Continued Efficacy and Safety of Zometa (Every 4 weeks vs Every 12 weeks) in Patients with Documented Bone Metastases from Breast Cancer
GCC 0723 - DRIT: A Prospective Correlative Drug Response Indicator (DRI) Tissue Analysis Study for Stage 3 and 4 Breast Cancer Patients
GCC 0725 - 0725 GCC: NSABP B40: A Randomized Phase III Trial Of Neoadjuvant Therapy in Patients with Palpable And Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (PCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for PCR with Each of the Regimens
GCC 0726 - 0726 GCC: S0307: A Phase 3 Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer
GCC 0755 - A Phase II, Randomized, Open-Label, Pilot Study to Evaulate the Safety and the Effects on Bone Resorption of AZD0530 in Patients With Prostate Cancer or Breast Cancer With Metastatic Bone Disease. D8180C00034
GCC 0818 - 0818 GCC: SNDX-275-0301: A Phase 2, Randomized, Double-Blind, Multicenter Study of Exemestane With and Without SNDX-275 in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer, Progressing on Treatment With A Non-Steroidal Aromatase Inhibitor
GCC 0849 - GCC 0849: Trastuzumab-MCC-DM1 Vs. Trastuzumab (Herceptin) And Docetaxel (Taxotere) In Patients With Metastatic HER2-Positive BC Who Have Not Received Prior Chemotherapy For Metastatic Disease
GCC 0850 - GCC 0850: Randomized Phase II Trial of Gemcitabine and Imatinib Mesylate Versus Gemcitabine Alone in Patients with Locally Advanced or Metastatic Breast Cancer
GCC 0902 - A Feasibility Study to Identify Microtentacles and Stem Cell Phenotype of Circulating Cancer Cells in Locally Advanced or Metastatic Breast Cancer
GCC 0914 - GCC 0914: A Dose-Escalation Study Of The Safety, Tolerability, And Pharmacokinetics Of Cabazitaxel In Combination With Cisplatin Administered Every 3 Weeks In Subjects With Advanced Solid Malignancies (TCD10870)
GCC 0920 - A randomized, double-blind, controlled phase III study of Stimuvax® (L-BLP25 or BLP25 liposome vaccine) in combination with hormonal treatment versus hormonal treatment alone for first-line therapy of post-menopausal women with estrogen receptor (ER)-positive and/or progesterone receptor (PgR)-positive, inoperable locally advanced, recurrent, or metastatic breast cancer- STRIDE - STimulating immune Response In aDvanced brEast cancer
GCC 0930 - A Multi-Center Randomized Controlled Double Blind Trial Assessing the Effect of Acupuncture in Reducing Musculoskeletal Symptoms in Breast Cancer Patients Taking Aromatase Inhibitors
GCC0761 - A Randomized Phase 2 Study of SCH 727965 in Subjects With Advanced Breast And Non-Small Cell Lung (NSCLC) Cancers
GCC0817 - A Phase Ib/IIa Trial of LBH589 in Combination with Trastuzumab in Adult Female Patients with HER2 Positive Metastatic Breast Cancer Whose Disease has Progressed During or Following Therapy with Trastuzumab.
N063D - N063D NCCTG: ALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study. A Randomised, Multi-Centre, Open-Label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients With HER2/ERBB2 Positive Primary Breast Cancer
NCIC MA27D - The Association of Breast Density Changes, Plasma Hormone Changes, and Breast Cancer Recurrence: A Companion Study to NCIC CTG MA.27
RTOG 0413 - NSABP PROTOCOL B-39 : A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer.
Email this Page
Print this Page
